- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00002414
Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia
Randomized, Double-Blind, Parallel Group, Placebo Controlled, Tolerability, Safety and Pilot Efficacy Study of CPI-1189 in HIV Infected Individuals With Cognitive and Motor Impairment
The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia.
Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.
Study Overview
Detailed Description
Late-stage HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.
Patients are randomized to receive either placebo or one of two oral doses of CPI-1189 daily. Patients are assessed for safety and tolerability during Weeks 2, 6, and 10. At Week 10, efficacy assessments are also made. For those who volunteer, a sample of cerebrospinal fluid is obtained at baseline and at Week 10. Blood samples for CPI-1189 pharmacokinetic trough measurements are taken at Weeks 2 and 10. The open-label phase starts at Week 11. At Weeks 13 and 16, a safety evaluation is performed. At the end of the open-label phase, Week 22, a final set of safety and efficacy assessments and a blood sample for CPI-1189 pharmacokinetic trough measurement are obtained.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 920930948
- Alzheimers Disease Research Ctr 0948 / UCSD
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern Univ / Dept of Neurology
-
-
Maryland
-
Baltimore, Maryland, United States, 212877609
- Johns Hopkins Hosp / Dept of Neurology / Meyer 6109
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington Univ Sch of Med / Dept of Neurology
-
-
New York
-
New York, New York, United States, 10032
- Columbia Univ / Sergievsky Ctr Physicians and Surgeons
-
Rochester, New York, United States, 14620
- Univ of Rochester / Strong Memorial Hosp
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
You may be eligible for this study if you:
- Are HIV-positive.
- Are at least 18 years old.
- Have symptoms of AIDS dementia including forgetfulness, loss of concentration, slow mental processing, or a loss of muscle control.
- Have been on stable anti-HIV drug therapy for the past 6 weeks (if you are taking anti-HIV drugs).
Exclusion Criteria
You will not be eligible for this study if you:
- Have certain serious medical conditions, such as a mental disorder or an opportunistic (AIDS-related) infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: Double
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Clifford DB
Publications and helpful links
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 289B
- CPI001189-ADC01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
Clinical Trials on CPI-1189
-
Centaur PharmaceuticalsCompletedHIV Infections | AIDS Dementia ComplexUnited States
-
Bioxodes S.A.Completed
-
Corvus Pharmaceuticals, Inc.Completed
-
ModernaTX, Inc.Active, not recruitingEpstein-Barr Virus InfectionUnited States
-
Massachusetts General HospitalCrisis Prevention InstituteCompleted
-
Coordination Pharmaceuticals, Inc.Completed
-
Coordination Pharmaceuticals, Inc.Completed
-
Washington University School of MedicineThe Foundation for Barnes-Jewish Hospital; MorphoSys AG; Swim Across America; Daniel...RecruitingMycosis Fungoides | Sezary Syndrome | Mycosis Fungoides/Sezary SyndromeUnited States
-
ModernaTX, Inc.Active, not recruitingEpstein-Barr Virus InfectionUnited States
-
Bioxodes S.A.Recruiting